N-Power Medicine

N-Power Medicine is a private, venture-backed biotech company founded in 2020 to transform the speed and efficiency of oncology clinical trials. By partnering with community oncology practices, it embeds research into standard care, creating a large-scale, prospective data network (the Kaleido Registry) to support pharmaceutical sponsors. Its human-in-the-loop, AI-powered platform aims to solve critical industry pain points: slow patient recruitment, lack of diverse trial populations, and high Phase III failure rates due to inadequate Phase II data. A strategic partnership with Merck and the acquisition of Syapse have significantly expanded its network and capabilities.

Human-in-the-loop, AI-powered platform that integrates prospective clinical data collection into routine community oncology workflows. It includes a secure EHR-agnostic point-of-care solution, embedded virtual staff, and automation tools to reduce clinician burden, enabling the creation of a large-scale, consented patient registry (Kaleido Registry) for external controls and trial acceleration.

N-Power competes with large, traditional Contract Research Organizations (CROs) that offer patient recruitment services, as well as a growing field of tech-enabled companies focused on clinical trial acceleration, decentralized trials, and real-world evidence (e.g., Tempus, Flatiron Health [owned by Roche], Medable). Its key differentiation is the 'always-on,' prospective data collection network embedded directly within community oncology workflows, aiming for deeper integration and higher-quality data than retrospective RWD aggregators.